Syon Capital LLC Lowers Holdings in Fresenius Medical Care AG (NYSE:FMS)

Syon Capital LLC decreased its stake in Fresenius Medical Care AG (NYSE:FMS) by 12.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,530 shares of the company’s stock after selling 2,301 shares during the quarter. Syon Capital LLC’s holdings in Fresenius Medical Care were worth $323,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Morningstar Investment Services LLC boosted its stake in shares of Fresenius Medical Care by 104.3% in the fourth quarter. Morningstar Investment Services LLC now owns 20,729 shares of the company’s stock worth $434,000 after buying an additional 10,584 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Fresenius Medical Care by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after buying an additional 1,799 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Fresenius Medical Care by 169.9% in the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after buying an additional 2,630 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Fresenius Medical Care by 164.6% in the fourth quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock worth $1,378,000 after buying an additional 41,139 shares during the last quarter. Finally, Guardian Capital Advisors LP boosted its position in Fresenius Medical Care by 16.7% during the fourth quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock worth $2,556,000 after purchasing an additional 17,725 shares in the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on FMS. Truist Financial increased their price target on Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. StockNews.com began coverage on Fresenius Medical Care in a research report on Monday. They set a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Price Performance

NYSE:FMS opened at $19.98 on Tuesday. The stock has a market cap of $11.72 billion, a PE ratio of 22.44, a P/E/G ratio of 1.10 and a beta of 0.93. Fresenius Medical Care AG has a one year low of $16.37 and a one year high of $27.72. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.14 and a current ratio of 1.50. The stock has a 50 day moving average price of $20.76 and a 200 day moving average price of $20.26.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.10. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. Equities research analysts expect that Fresenius Medical Care AG will post 1.5 EPS for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently announced an annual dividend, which was paid on Monday, June 3rd. Investors of record on Monday, May 20th were issued a $0.437 dividend. The ex-dividend date of this dividend was Friday, May 17th. This represents a yield of 2.35%. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 49.44%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.